The immunomodulatory effects of the combination therapy improved local control of RT and reduced systemic pulomonary metastases, thus providing a strong rationale for combining RT with TLR9 agonist immunotherapy for improved loco-regional and systemic tumor therapy. Here, TLR9 is linked to neoplasm.